Abstract
Somatostatin receptor type 2 (SST2) is the main pharmacological target of medical therapy for GH-secreting pituitary tumors, but molecular mechanisms regulating its expression and signaling are largely unknown. The aim of this study was to investigate the role of cytoskeleton protein filamin A (FLNA) in SST2 expression and signaling in somatotroph tumor cells. We found a highly variable expression of FLNA in human GH-secreting tumors, without a correlation with SST2 levels. FLNA silencing in human tumoral cells did not affect SST2 expression and localization but abolished the SST2-induced reduction of cyclin D1 (-37% ± 15% incontrol cells, P
Original language | English |
---|---|
Pages (from-to) | 2932-2941 |
Number of pages | 10 |
Journal | Endocrinology |
Volume | 155 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2014 |
ASJC Scopus subject areas
- Endocrinology